In acute management of TIA, what is the role of tPA therapy?

• A. It is used regardless of symptom duration
• B. It is indicated if symptoms last less than 24 hours
• C. It is contraindicated in all cases
• D. It can be given even if hemorrhagic signs are present

Answer: (B)

The role of tPA (tissue plasminogen activator) therapy in the acute management of transient ischemic attacks (TIAs) is specific to the duration of symptoms. tPA is a thrombolytic agent indicated for the treatment of acute ischemic stroke, and its administration is contingent upon the time frame of symptom onset.

In the context of acute management of a TIA, tPA is indicated if the symptoms have lasted less than 24 hours. However, it is particularly important to note that the use of tPA is most effective when administered within a strict time window, typically within 3 to 4.5 hours of symptom onset for stroke patients. While TIAs themselves are characterized by symptoms that resolve spontaneously within 24 hours, the link to thrombolytics primarily relates to the understanding that TIAs are often precursor events to full-blown strokes.

If symptoms resolve quickly and the clinical evaluation suggests a minor or transient event, the use of tPA is not standard practice outside of an acute stroke protocol, which is highly focused on timing. Therefore, the indication for tPA therapy as the acute management strategy relies heavily on the 24-hour symptom resolution window, underscoring the urgency and the critical nature of timing